OncRef

Clinical Trial: NCT05009329

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Allist Pharmaceuticals, Inc.
Information Provided By:Allist Pharmaceuticals, Inc.
Last Update Posted:2026-08-13

Study Overview

Brief Summary

To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.

Official Title

Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation

Conditions

NSCLC, Solid Tumor

Intervention / Treatment

  • Drug: JAB-21822
  • Drug: JAB-21822
  • Drug: JAB-21822

Other Study ID Numbers

  • JAB-21822-1002

Start Date (Actual)

2021-07-26

Primary Completion Date (Estimated)

2026-08

Study Completion Date (Estimated)

2026-12

Enrollment (Actual)

315

Study Type

Interventional

Phase

Phase 1, Phase 2